-
-
-
-
-
-
-
Ocuphire Appoints Rick Rodgers as Interim Chief Executive Officer
-
-
-
-
-
-
-
Ocuphire Announces Late-Breaking Paper for Nyxol for Reversal of Dilation Indication at Annual ASRS Meeting and Five More Presentations at Conferences in July
-
-
-
-
-
-
-
Ocuphire Pharma Announces Upcoming Presentations at the Retina World Congress, Clinical Trials at the Summit, and the H.C. Wainwright Global Investment Conference
-
-
-
-
-
-
-
Ocuphire Pharma (OCUP) Reports Positive Topline Results from MIRA-3 Phase 3 FDA Registration Trial for Nyxol
-
-
-
-
-
-
-
Ocuphire Pharma (OCUP) to Present Data and Updates on APX3330 and Nyxol
-
-
-
-
-
-
-
Ocuphire Announces Financial Results for the Third Quarter 2021 and Provides Corporate Update
-
-
-
-
-
-
-
Ocuphire Pharma Presenting at Two Conferences in August
-
1,155,367 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

